NO124275B - - Google Patents
Download PDFInfo
- Publication number
- NO124275B NO124275B NO170186A NO17018667A NO124275B NO 124275 B NO124275 B NO 124275B NO 170186 A NO170186 A NO 170186A NO 17018667 A NO17018667 A NO 17018667A NO 124275 B NO124275 B NO 124275B
- Authority
- NO
- Norway
- Prior art keywords
- nitro
- amino
- alkylidene
- furyl
- chemotherapeutic
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 15
- 230000000973 chemotherapeutic effect Effects 0.000 description 7
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04C—STRUCTURAL ELEMENTS; BUILDING MATERIALS
- E04C3/00—Structural elongated elements designed for load-supporting
- E04C3/02—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces
- E04C3/04—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces of metal
- E04C3/06—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces of metal with substantially solid, i.e. unapertured, web
- E04C3/07—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces of metal with substantially solid, i.e. unapertured, web at least partly of bent or otherwise deformed strip- or sheet-like material
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04B—GENERAL BUILDING CONSTRUCTIONS; WALLS, e.g. PARTITIONS; ROOFS; FLOORS; CEILINGS; INSULATION OR OTHER PROTECTION OF BUILDINGS
- E04B1/00—Constructions in general; Structures which are not restricted either to walls, e.g. partitions, or floors or ceilings or roofs
- E04B1/38—Connections for building structures in general
- E04B1/48—Dowels, i.e. members adapted to penetrate the surfaces of two parts and to take the shear stresses
- E04B1/49—Dowels, i.e. members adapted to penetrate the surfaces of two parts and to take the shear stresses with self-penetrating parts, e.g. claw dowels
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04C—STRUCTURAL ELEMENTS; BUILDING MATERIALS
- E04C3/00—Structural elongated elements designed for load-supporting
- E04C3/02—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces
- E04C3/29—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces built-up from parts of different material, i.e. composite structures
- E04C3/292—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces built-up from parts of different material, i.e. composite structures the materials being wood and metal
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B15/00—Nails; Staples
- F16B15/0023—Nail plates
- F16B15/003—Nail plates with teeth cut out from the material of the plate
- F16B15/0046—Nail plates with teeth cut out from the material of the plate from the body of the plate
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04C—STRUCTURAL ELEMENTS; BUILDING MATERIALS
- E04C3/00—Structural elongated elements designed for load-supporting
- E04C3/02—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces
- E04C3/04—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces of metal
- E04C2003/0486—Truss like structures composed of separate truss elements
-
- E—FIXED CONSTRUCTIONS
- E04—BUILDING
- E04C—STRUCTURAL ELEMENTS; BUILDING MATERIALS
- E04C3/00—Structural elongated elements designed for load-supporting
- E04C3/02—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces
- E04C3/04—Joists; Girders, trusses, or trusslike structures, e.g. prefabricated; Lintels; Transoms; Braces of metal
- E04C2003/0486—Truss like structures composed of separate truss elements
- E04C2003/0491—Truss like structures composed of separate truss elements the truss elements being located in one single surface or in several parallel surfaces
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B15/00—Nails; Staples
- F16B15/0023—Nail plates
- F16B2015/0061—Multipiece-plates
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B15/00—Nails; Staples
- F16B15/0023—Nail plates
- F16B2015/0069—Nail plates with nails on both sides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S411/00—Expanded, threaded, driven, headed, tool-deformed, or locked-threaded fastener
- Y10S411/921—Multiple-pronged nail, spike or tack
Landscapes
- Engineering & Computer Science (AREA)
- Architecture (AREA)
- Structural Engineering (AREA)
- Civil Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Electromagnetism (AREA)
- Physics & Mathematics (AREA)
- Mechanical Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Joining Of Building Structures In Genera (AREA)
- Rod-Shaped Construction Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Fremgangsmåte for fremstilling av N-(5-nitro-2-furyl)-alkyliden- 3 - amino - 2 - oksazoli doner. Process for the preparation of N-(5-nitro-2-furyl)-alkylidene-3-amino-2-oxazolides.
Foreliggende oppfinnelse vedrører fremstillingen av nye kjemiske forbindelser, The present invention relates to the production of new chemical compounds,
omfattende N-(5-nitro-2-furyl)-alkyliden-3-amino-2-oksazolidoner, som utøver en comprising N-(5-nitro-2-furyl)-alkylidene-3-amino-2-oxazolidones, which exert a
høy grad av in vivo kjemoterapeutisk effektivitet mot mikr obeinf eks joner ved oral high degree of in vivo chemotherapeutic effectiveness against microbeinf ex ions by oral
administrasjon, og som pasienten tåler godt administration, and which the patient tolerates well
når legemidlet administreres på denne when the medicine is administered on this
måten. the way.
N- (5-nitro-2-f uryl) -alkyliden-3-amino-2-oksazolidoner fåes i henhold til foreliggende oppfinnelse og representeres av føl-gende generelle formel: N-(5-nitro-2-furyl)-alkylidene-3-amino-2-oxazolidones are obtained according to the present invention and are represented by the following general formula:
hvor where
R er hydrogen eller en alkylgruppe, og R is hydrogen or an alkyl group, and
Ri, Ri-, R.i og Ri er hydrogen eller et R 1 , R 1 -, R 1 and R 1 are hydrogen or et
alkyl, hydroksyalkyl eller halogenalkylgruppe. alkyl, hydroxyalkyl or haloalkyl group.
De i henhold til oppfinnelsen fortrinns-vis fremstilte forbindelser, som har en The compounds preferably produced according to the invention, which have a
særlig høy aktivitet, er slike hvor particularly high activity, are such where
R er en metyl- eller etylgruppe eller R is a methyl or ethyl group or
fortrinsvis hydrogen, og preferably hydrogen, and
Ri, Ri, Rn, R4 er hydrogen eller et lavere alkyl, hydroksy-lavere alkyl eller en R1, R1, Rn, R4 are hydrogen or a lower alkyl, hydroxy-lower alkyl or a
h alogenalkylgruppe. h haloalkyl group.
Det er kjent at nitrofuraner som klasse It is known that nitrofurans as a class
er i besittelse av antibakteriell aktivitet. Disse antibakterielle nitrofuraner kan inn-deles i to grupper: (1) Forbindelser hvis anvendelse er begrenset til lokal administrasjon, og (2) forbindelser som også ut-øver kjemoterapeutisk aktivitet ved oral administrasjon. Forbindelser i den annen gruppe har hittil vært beheftet med den possesses antibacterial activity. These antibacterial nitrofurans can be divided into two groups: (1) Compounds whose use is limited to local administration, and (2) compounds which also exert chemotherapeutic activity by oral administration. Connections in the second group have so far been affected by it
uheldige egenskap at de ofte forårsaker unfortunate characteristics that they often cause
kvalme og oppkast når de administreres i en tilstrekkelig mengde til å tjene som kjemoterapeutiske midler. Dette har også nausea and vomiting when administered in sufficient quantity to serve as chemotherapeutic agents. This also has
medført at slike forbindelser har fått en begrenset anvendelse. resulting in such compounds having a limited use.
Vi har gjort den overraskende oppda-gelse at N-(5-nitro-2-furyl)-alkyliden-3-amino-2-oksazolidonene som fremstilles i henhold til foreliggende oppfinnelse, er i besittelse av en høy grad av antibakteriell aktivitet, slik som tidligere kjente nitrofuraner, og også er i besittelse av den kjemoterapeutiske effektivitet som karakteri-serer den gruppe av tidligere kjente nitrofuraner som kunne administreres oralt, men de nye forbindelser atskiller seg i ut-preget grad fra disse tidligere kjente ved at de i bemerkelsesverdig grad er fri for de ubehagelige og ikke ønskede virkninger som bevirker kvalme og oppkast når de administreres oralt i en mengde som er tilstrekkelig til å bevirke en høy grad av beskyttelse. Anvendelsen av stoffene er ikke ledsaget av den risiko at den som gis legemidlet er ute av stand til å beholde det, således at det ikke kan utøve den ønskede terapeutiske funksjon. We have made the surprising discovery that the N-(5-nitro-2-furyl)-alkylidene-3-amino-2-oxazolidones produced according to the present invention possess a high degree of antibacterial activity, as like previously known nitrofurans, and also possess the chemotherapeutic effectiveness that characterizes the group of previously known nitrofurans that could be administered orally, but the new compounds differ to a marked degree from these previously known ones in that they remarkably are free from the unpleasant and undesired effects of causing nausea and vomiting when administered orally in an amount sufficient to effect a high degree of protection. The use of the substances is not accompanied by the risk that the person who is given the medicine is unable to retain it, so that it cannot exercise the desired therapeutic function.
Disse nye forbindelser har vist seg ved behandling av dyr som er dødelig infisert med patogene organismer, å være i besittelse av helbredende egenskaper i en for-bausende høy grad: Beskyttelse av størrel-sesorden 100 pst. oppnåes etter infeksjon av dyr som er dødelig infisert med S. ty-phosa og V; comma. Salmonella er årsaken til tyfoidfeber eller tyfus for hvilken syk-dom der ennå ikke er funnet noe virkelig virksomt kjemoterapeutisk middel. V. comma-basillen er årsaken til kolera, en syk-dom av epidemisk karakter i enkelte land. Doseringen som per os er nødvendig for å oppnå en høy grad av kjemoterapeutisk beskyttelse i dyr, som på en dødelig måte er infisert med disse organismer, er meget moderat og fremkaller ikke noe utslag av forgiftningsfenomener. Den høye terapeutiske kraft av disse nye forbindelser til-later doseringer med hensiktsmessige tids-intervaller som er i overensstemmelse med de vanlige arbeidsmetoder — en innle-dende dose som etterfølges av ytterligere doser med bestemte intervaller og i enkelte tilfeller en første dose eller en eneste dose, som kan tjene som den eneste administrasjon av legemidlet, og den samme høye grad av kjemoterapeutisk effektivitet kan oppnåes fra en eneste dose som fra et større antall av gjentatte doser. These new compounds have been shown, in the treatment of animals fatally infected with pathogenic organisms, to possess curative properties to a surprisingly high degree: Protection of the order of 100 percent is achieved after infection of animals fatally infected with S. typhosa and V; comma. Salmonella is the cause of typhoid fever or typhoid for which no really effective chemotherapeutic agent has yet been found. The V. comma bacillus is the cause of cholera, a disease of an epidemic nature in some countries. The dosage which per os is necessary to obtain a high degree of chemotherapeutic protection in animals, which are lethally infected with these organisms, is very moderate and does not produce any effects of poisoning phenomena. The high therapeutic potency of these new compounds allows dosages at convenient time intervals that are consistent with the usual methods of work — an initial dose followed by further doses at specific intervals and in some cases a first dose or a single dose , which may serve as the sole administration of the drug, and the same high degree of chemotherapeutic efficacy may be obtained from a single dose as from a greater number of repeated doses.
Fremstillingen av disse nye forbindelser på en måte som vil tillate oral administrasjon av dem, er lett. Den spesielle forbindelse som velges for å brukes, kan inn-føres i tabletter eller i pastiller. Slike tabletter sammensettes på vanlig måte ved å granulere forbindelsen med en vanlig sti-velsespasta, derpå tørkes og der tilsettes tørr stivelse, og tablettene presses ut. Pa-stillene sammensettes på vanlig måte også ved granulering med sukkersirup og derpå tilsettes fyllstoffet i form av pulverisert sukker, tørr stivelse og et smaksmaterial. The preparation of these new compounds in a manner that will permit their oral administration is easy. The particular compound chosen to be used can be introduced in tablets or lozenges. Such tablets are composed in the usual way by granulating the compound with a common starch-welding paste, then drying and dry starch is added there, and the tablets are pressed out. The pa stills are composed in the usual way also by granulation with sugar syrup and then the filler is added in the form of powdered sugar, dry starch and a flavoring material.
De forskjellige nye forbindelser er noe forskjellige fra hverandre med hensyn til graden av kjemoterapeutisk effektivitet. Den forbindelse som vi nå foretrekker, og som der er oppnådd utmerkete resultater med, er N-(5-nitro-2-furfuryliden)-3-amino-2-oksazolidon. Tabletter eller pastiller som inneholder denne forbindelse, tåles godt når de administreres oralt og utøver overordentlig sterke kjemoterapeutiske virkninger. The various new compounds differ somewhat from each other in terms of their degree of chemotherapeutic efficacy. The compound which we now prefer, and with which excellent results have been obtained, is N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone. Tablets or lozenges containing this compound are well tolerated when administered orally and exert extremely strong chemotherapeutic effects.
I overensstemmelse med oppfinnelsen tilveiebringes der en fremgangsmåte for fremstilling av disse N-(5-nitro-2-furyl)-alkyliden-3-amino-2-oksazolidoner, som er karakterisert ved at N-(5-nitro-2-furyl)- In accordance with the invention, a method for the production of these N-(5-nitro-2-furyl)-alkylidene-3-amino-2-oxazolidones is provided, which is characterized in that N-(5-nitro-2-furyl) -
alkyliden-3-amirio-2-imino-oksazolidin, re-presentert ved følgende generelle formel: alkylidene-3-amirio-2-imino-oxazolidine, represented by the following general formula:
hvor where
R, Ri, R2, R.-i og R4 har den samme be-tydning som ovenfor angitt, hydrolyseres til det tilsvarende oksazolidon. R, R1, R2, R1 and R4 have the same meaning as indicated above, are hydrolyzed to the corresponding oxazolidone.
Fremstillingen av de nye forbindelser i henhold til oppfinnelsen skal klargjøres ved følgende eksempel: Eksempel: En oppløsning av 51 g av N-(5-nitro-2-furfuryliden)-3-amino-2-irnino-oksazoli-dinhydroklorid i 1000 cm<3> vann filtreres for å fjerne eventuelt uoppløselig material og behandles derpå under tilbakeløp i 1 time, og krystaller skilles ut etter en kort koketid. Blandingen filtreres varm og det gule uoppløselig faste stoff vaskes med vann og derpå med alkohol. Etter tørking andrar N-(5-nitro-2-furfuryliden)-3-amino-2-oksazolidonet til 21,8 g, 54,5 pst., smeltepunkt 254—256° C. The production of the new compounds according to the invention is to be clarified by the following example: Example: A solution of 51 g of N-(5-nitro-2-furfurylidene)-3-amino-2-irnino-oxazolide hydrochloride in 1000 cm< 3> water is filtered to remove any insoluble material and then treated under reflux for 1 hour, and crystals are separated after a short boiling time. The mixture is filtered hot and the yellow insoluble solid is washed with water and then with alcohol. After drying, the N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone yields 21.8 g, 54.5%, mp 254-256°C.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US591788A US3416283A (en) | 1966-11-03 | 1966-11-03 | Combination wood and metal trusses |
Publications (1)
Publication Number | Publication Date |
---|---|
NO124275B true NO124275B (en) | 1972-03-27 |
Family
ID=24367941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO170186A NO124275B (en) | 1966-11-03 | 1967-10-18 |
Country Status (7)
Country | Link |
---|---|
US (1) | US3416283A (en) |
BE (1) | BE706052A (en) |
DE (1) | DE1659225C3 (en) |
DK (1) | DK128915B (en) |
GB (1) | GB1159177A (en) |
NO (1) | NO124275B (en) |
SE (1) | SE322613B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3498170A (en) * | 1966-10-20 | 1970-03-03 | Sanford Arthur C | Connector plate combination |
US3531904A (en) * | 1968-06-17 | 1970-10-06 | Sanford Arthur C | Reinforced construction for wood stress members |
US3603197A (en) * | 1969-09-29 | 1971-09-07 | Gordon G Wood | Truss connector plate |
US3875650A (en) * | 1973-03-05 | 1975-04-08 | Steel Web Corp | Method of making a trussed joist structure |
US3841195A (en) * | 1973-05-15 | 1974-10-15 | Automated Building Components | Two-sided fastener |
US3963452A (en) * | 1974-10-04 | 1976-06-15 | Automated Building Components, Inc. | Connector plate stock |
US4002116A (en) * | 1975-05-09 | 1977-01-11 | Jack N. Schmitt | Apparatus for forming trusses |
USRE31807E (en) * | 1975-05-09 | 1985-01-22 | Truss-web connector | |
US4031686A (en) * | 1977-01-13 | 1977-06-28 | Sanford Arthur C | Combination wood and metal truss structure |
US4143500A (en) * | 1978-03-13 | 1979-03-13 | Sanford Arthur C | End bearing construction for truss |
US4207719A (en) * | 1978-04-03 | 1980-06-17 | James Knowles | Composite construction beam |
US4295318A (en) * | 1979-07-26 | 1981-10-20 | Monex Corporation | Connector for wooden truss |
US4348850A (en) * | 1979-08-06 | 1982-09-14 | Moehlenpah Industries, Inc. | Web member |
US4475328A (en) * | 1979-08-06 | 1984-10-09 | Moehlenpah Industries, Inc. | Web member |
GB2127457B (en) * | 1982-09-24 | 1986-03-12 | Gang Nail Systems Inc | Attachment member for connecting two spaced wooden beams truss |
SE447287B (en) * | 1985-03-22 | 1986-11-03 | Kindberg Bengt Ake | BALK AND SET FOR MANUFACTURING THEREOF |
FI74319C (en) * | 1986-02-13 | 1988-01-11 | Metsae Serla Oy | FOGORGAN FOER FOGNING AV TRAEBALKAR VID VARANDRA. |
BE1001019A3 (en) * | 1987-11-06 | 1989-06-13 | Jacques Willens | Load-bearing beam for building - has timber lengthwise elements joined by rods, e.g. of metal or concrete, with adhesive joints |
US5392908A (en) * | 1994-04-25 | 1995-02-28 | Tee-Lok Corporation | Package for shipping, storing, and handling truss plates and method for forming same |
US5634319A (en) * | 1995-03-27 | 1997-06-03 | Tee-Lok Corporation | Truss plate bundle identification system |
FI98444C (en) * | 1995-08-04 | 1997-06-25 | Mitek Holdings Inc | Apparatus for packaging nail plates or the like |
US5906264A (en) * | 1997-09-09 | 1999-05-25 | Tee-Lok Corporation | Apparatus and method for producing truss plate bundles |
US5996303A (en) * | 1999-02-18 | 1999-12-07 | Mitek Holdings, Inc. | Truss with alternating metal web |
US6412246B1 (en) * | 1999-04-30 | 2002-07-02 | Mitek Holdings, Inc. | Structural truss |
US6758022B1 (en) * | 1999-08-25 | 2004-07-06 | Mitek Holdings, Inc. | Structural framework and webs therefor |
AUPR666701A0 (en) * | 2001-07-27 | 2001-08-23 | Mitek Holdings, Inc. | Structural framework, method for forming the framework and webs therefor |
AU2002952898A0 (en) * | 2002-11-22 | 2002-12-12 | Tec-Truss Holdings Pty Ltd | Composite beams |
US6892502B1 (en) | 2003-03-26 | 2005-05-17 | David A. Hubbell | Space frame support structure employing weld-free, single-cast structural connectors for highway signs |
US8166724B2 (en) * | 2009-02-18 | 2012-05-01 | Solive Ajouree 2000 Inc. | Top-chord bearing wooden joist and method |
GB2506198B (en) * | 2012-09-25 | 2020-04-22 | Illinois Tool Works | Anchorage enhancer plate |
DE102019126399A1 (en) * | 2019-09-30 | 2021-04-01 | Konecranes Global Corp. | Carrier for a trolley and overhead transport device with such a carrier |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1438575A (en) * | 1922-01-21 | 1922-12-12 | Joseph A Brown | Railroad spike |
FR1199914A (en) * | 1957-07-19 | 1959-12-17 | wooden lattice-type construction element, in particular beam | |
US3025577A (en) * | 1959-03-09 | 1962-03-20 | Automated Building Components | Structural element |
FR1252668A (en) * | 1959-12-09 | 1961-02-03 | Improvements to fixed or animated projection devices | |
US3172171A (en) * | 1961-09-11 | 1965-03-09 | Automated Building Components | Connector |
US3211043A (en) * | 1962-05-21 | 1965-10-12 | Sanford Ind Inc | Corrugated connector plate having notched teeth |
US3304106A (en) * | 1963-09-30 | 1967-02-14 | Automated Building Components | Truss and connector plates therefor |
US3298151A (en) * | 1964-09-16 | 1967-01-17 | Automated Building Components | Truss with multi-tooth connector |
US3336706A (en) * | 1966-07-28 | 1967-08-22 | Arthur L Troutner | Composite truss joist with lower chord bearing |
-
1966
- 1966-11-03 US US591788A patent/US3416283A/en not_active Expired - Lifetime
-
1967
- 1967-10-13 GB GB46746/67A patent/GB1159177A/en not_active Expired
- 1967-10-18 NO NO170186A patent/NO124275B/no unknown
- 1967-10-28 DE DE1659225A patent/DE1659225C3/en not_active Expired
- 1967-10-31 SE SE14927/67A patent/SE322613B/xx unknown
- 1967-11-02 DK DK546767AA patent/DK128915B/en unknown
- 1967-11-03 BE BE706052D patent/BE706052A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US3416283A (en) | 1968-12-17 |
BE706052A (en) | 1968-03-18 |
DE1659225A1 (en) | 1971-09-23 |
DE1659225C3 (en) | 1974-10-17 |
DE1659225B2 (en) | 1974-03-14 |
DK128915B (en) | 1974-07-22 |
GB1159177A (en) | 1969-07-23 |
SE322613B (en) | 1970-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO124275B (en) | ||
US3564100A (en) | Basically substituted cycloalkene compounds as antitussive agents | |
US3011945A (en) | Phenylcyclopropylamine -10-(omega-aminoalkyl)-phenothiazine ataractic composition | |
US3439094A (en) | Analgesic compositions containing namol xenyrate,caffeine and acetyl-rho-aminophenol | |
US4002758A (en) | Medicament which is utilizable in ophthalmology | |
JPS5938203B2 (en) | A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q. | |
US3144387A (en) | Anti-inflammatory compositions | |
US3993767A (en) | Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy | |
Zeenat et al. | An appraisal of medicinal properties of Shibb-e-Yamani (Alum): a review | |
US5026706A (en) | Method for treating dysuria using naftopidil | |
US3039927A (en) | Pharmaceutical composition comprising aspirin and sorbitol | |
HOEKENGA et al. | Jarisch-Herxheimer reaction in neurosyphilis treated with penicillin | |
US2847416A (en) | Nu-[1-(5-nitro-2-furyl) ethylidene]-3-amino-2-oxazolidone | |
US3175943A (en) | Process for stimulating choleresis | |
DE2221281C3 (en) | Pharmaceutical preparations with anti-inflammatory and analgesic effects | |
DE2432393A1 (en) | MEDICINAL PREPARATION FOR TREATMENT OF BOES-LIKE NEW FORMATIONS | |
US3150043A (en) | Anorectic composition | |
US3952103A (en) | Herpes viral infection treatment | |
US4062974A (en) | Method for treating drepanocytosis | |
JPH0499723A (en) | Virus-genomic inactivator | |
WO1992016208A1 (en) | Use of benzimidazole anthelmintic in the treatment of microsporidial infections | |
US7306816B1 (en) | Medicinal plant compositions of matter and method of preparation | |
RU2119792C1 (en) | Preparation for treatment of animals with piroplasmosis and method of its using | |
US3074848A (en) | 2-hydroxy-5,2'-dichloro-4'-nitrobenzanilide for combating tapeworms | |
JPS63208519A (en) | Carcinogenic promoting substance inhibitor |